Lexaria BioscienceLEXX
LEXX
About: Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
Employees: 7
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
1.2% less ownership
Funds ownership: 8.26% [Q4 2024] → 7.06% (-1.2%) [Q1 2025]
12% less funds holding
Funds holding: 25 [Q4 2024] → 22 (-3) [Q1 2025]
30% less capital invested
Capital invested by funds: $3.03M [Q4 2024] → $2.12M (-$907K) [Q1 2025]
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$4
337%
upside
Avg. target
$4
337%
upside
High target
$4
337%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen | 337%upside $4 | Buy Maintained | 29 Jul 2025 |
Financial journalist opinion
Based on 4 articles about LEXX published over the past 30 days
Neutral
Accesswire
2 days ago
Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus® DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus® DehydraTECH-GLP-1 study arms evidencing patient safety and tolerability consistent with the primary study endpoint KELOWNA, BC / ACCESS Newswire / July 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following partial 8-week positive interim results update on the phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study" or the "Lexaria Study"), currently underway in Australia, focusing on the DehydraTECH ("DHT") glucagon-like peptide-1 ("GLP-1") study arms 2 and 5 relative to the Rybelsus® control study arm 4. "We are extremely encouraged by the interim results received to date aligned with our primary study endpoint," said Richard Christopher, CEO of Lexaria.
Neutral
TheNewswire
2 days ago
Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study
DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus
Neutral
Accesswire
1 week ago
Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effects DehydraTECH reduces side effects and could support patient retention and further industry growth DehydraTECH is the only technology publicly disclosed for its ability to reduce side effects in all 3 of the top GLP-1 drugs currently sold in the world today: semaglutide, tirzepatide, and liraglutide KELOWNA, BC / ACCESS Newswire / July 23, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") strategic update as the industry continues to outperform earlier revenue growth projections. Global pharmaceutical corporations are competing desperately to secure either a foothold, or dominance, in what is currently the fastest growing pharmaceutical sector in the world: GLP-1 weight loss and diabetes control.
Neutral
TheNewswire
1 week ago
Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effects DehydraTECH reduces side effects and could support patient retention and further industry growth
Neutral
Accesswire
1 month ago
Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
New patents received for the treatment of epilepsy and for the sublingual delivery of nicotine KELOWNA, BC / ACCESS Newswire / June 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that it has received 2 new international patents. This now brings Lexaria's total worldwide patent portfolio to 50.
Neutral
TheNewswire
1 month ago
Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
New patents received for the treatment of epilepsy and for the sublingual delivery of nicotine Kelowna, British Columbia – June 23, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that it has received 2 new international patents. This now brings Lexaria's total worldwide patent portfolio to 50.
Neutral
Accesswire
1 month ago
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (“AEs”) as compared to injected liraglutide (Saxenda(R)) Lexaria has now demonstrated, in distinct human clinical studies, clear reductions in AEs utilizing its patented DehydraTECH technology with all of the three major GLP-1 drugs sold in the world today: liraglutide, semaglutide and tirzepatide KELOWNA, BC / ACCESS Newswire / June 11, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that human study GLP-1-H25-5 (the "Study") which compared oral capsules of DehydraTECH-liraglutide to injected Saxenda®-branded liraglutide has been successfully completed with partial results now available. In distinct clinical human studies, Lexaria has now demonstrated clear reductions in AEs utilizing oral DehydraTECH versions of all three of the major GLP-1 drugs sold in the world today: liraglutide, semaglutide, and tirzepatide.
Neutral
TheNewswire
1 month ago
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (“AEs”) as compared to injected liraglutide (Saxenda®) Lexaria has now demonstrated, in distinct human clinical studies, clear reductions in AEs utilizing its patented DehydraTECH technology with all of the three major GLP-1 drugs sold in the world today: liraglutide, semaglutide and tirzepatide
Neutral
TheNewswire
1 month ago
Lexaria Attending BIO International Convention
Biotechnology Sector's Premier Strategic Partnering Event Kelowna, British Columbia – June 5, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that its Chief Executive Officer and President and Chief Scientific Officer will be attending the BIO International Convention (“BIO”) in Boston, June 16-19.
Neutral
Accesswire
1 month ago
Lexaria Attending BIO International Convention
Biotechnology Sector's Premier Strategic Partnering Event KELOWNA, BC / ACCESS Newswire / June 5, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that its Chief Executive Officer and President and Chief Scientific Officer will be attending the BIO International Convention ("BIO") in Boston, June 16-19. With over 1,500 exhibitors and 20,000 attendees, BIO is the largest biotechnology convention in the world.
Charts implemented using Lightweight Charts™